Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Name: Αlpha¹ Rigor Record — Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.
Item: Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.
Rating: 59
Author: Αlpha¹

Debily MA, Le Teuff G, Kergrohen T, Varlet P, Castel D, Leblond P, Hargrave D, Nysom K, Blomgren K, McCowage GB, Bautista F, van Vuurden D, Jones C, Mackay A, Izquierdo E, Ziegler DS, Moussa A, Barret E, Puget S, Beccaria K, Aquilina K, Riffaud L, Bolle S, Abbou S, Bertozzi AI, De Carli E, Boddaert N, Dangouloff-Ros V, Calmon R, Blanc P, Vassal G, Le Deley MC, Grill J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 2 high issues for “Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 2 trial with rigorous design, clear reporting of methods, and appropriate statistical analysis. The main weakness is the lack of an explicit ethics approval statement naming the committee and approval number, and minor reporting gaps such as not explicitly stating the open-label design and not mentioning a reporting guideline.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with N/A for animal-related and cell-line criteria. The statistics verification recomputed only a subset of tests (3 tests, 2 consistent, 1 inconsistent but unspecified), so the statistical analysis is not fully verified.

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks. 1 printed percentage that does not match its own count.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on DIPG molecular characterization, actionable targets (EGFR, mTOR, PDGFRA), and preclinical/clinical evidence for the three drugs. It acknowledges the lack of effective chemotherapy and the need for targeted approaches. The rationale for the trial design is clearly linked to the premise, and limitations of prior single-arm trials are implicitly addressed by the randomized design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on DIPG biology, targeted therapies, and the rationale for biomarker-driven randomization.

Evidence

direct quote[Introduction, paragraphs 1-3]

“In the past two decades, the reintroduction of stereotactic biopsies and increased autopsy studies – have helped identifiy actionable targets, such as PDGFRA – , EGFR , and mTOR .”